文献速递泌尿男性生殖肿瘤

转移性乳头状肾细胞癌中PD-L1的表达及其预后价值:GETUG多中心回顾性队列研究结果

PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
PubMed 文献 · Eur J Cancer · 2024-05-13

该研究在GETUG多中心回顾性队列的68例转移性乳头状肾细胞癌(pRCC)组织中,用免疫组化分析PD-L1、PD-1、PD-L2、LAG-3及血管生成标志物(CAIX、c-MET)。27.9%肿瘤PD-L1阳性,PD-L1阳性与更短的总生存显著相关(多因素分析HR=4.0,p=0.01)。

要点

  • 转移性pRCC中27.9%为PD-L1阳性,PD-L1阳性者总生存显著更短(HR=4.0,p=0.01)。
  • PD-L2表达45.6%,PD-1为17.6%,LAG-3为19.1%,均与PD-L1表达无相关性。
  • 66%(45/68)表达至少一种免疫标志物,43%(29/68)同时表达免疫和血管生成标志物。

核心结论

  • PD-L1表达是转移性pRCC的不良预后因素,该多中心队列结果强化了ICI在转移性pRCC治疗中预期获益的临床数据。

研究设计与样本

  • GETUG多中心回顾性队列研究,对68例转移性pRCC组织行免疫组化分析免疫标志物(PD-L1、PD-1、PD-L2、LAG-3)和血管生成通路标志物(CAIX、c-MET)。

主要发现

  • 27.9%的肿瘤为PD-L1阳性;PD-L2表达更常见(45.6%),PD-1和LAG-3阳性率分别为17.6%和19.1%。
  • 上述免疫标志物均与PD-L1表达无相关性。
  • 66%(45/68)表达至少一种免疫标志物,43%(29/68)为「双阳性」,即同时表达免疫和血管生成标志物。
  • PD-L1阳性pRCC患者的总生存显著更短;多因素分析证实PD-L1表达与更短总生存显著相关(HR=4.0,p=0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Papillary renal cell carcinoma (pRCC) is a rare and aggressive cancer with no specifically established therapeutic strategy in the metastatic setting. Combinations of tyrosine kinase and immune checkpoint inhibitors (ICI) are a promising option. We aimed to study the immune landscape of metastatic pRCC, and its interactions with angiogenesis pathways, to search for potential therapeutic targets. METHODS: The expression of immune markers (PD-L1, PD-1, PD-L2, LAG-3) and angiogenic pathways (CAIX, c-MET), was analyzed by immunohistochemistry on 68 metastatic pRCC retrieved from a retrospective multicenter GETUG cohort. Our primary endpoint was to estimate the prevalence of PD-L1 expression and its prognostic impact in metastatic pRCC. Secondary endpoints included the evaluation of other immune markers (PD-1, PD-L2, and LAG-3) and their association with PD-L1. We also assessed angiogenic markers and their association with PD-L1. RESULTS: Overall, 27.9 % of tumors were PD-L1 positive. PD-L2 was more frequently expressed (45.6 %), PD-1 and LAG-3 were positive in 17.6 % and 19.1 % respectively. None of these markers was correlated with PD-L1 expression. 66 % (45/68) expressed at least one immune marker, and 43 % (29/68) were "double-positive", as they expressed both immune and angiogenic markers. OS was significantly shorter for patients with PD-L1 positive pRCC. A multivariate analysis confirmed a significant association between PD-L1 expression and shorter overall survival (HR = 4.0, p = 0.01). CONCLUSION: These results reinforce clinical data on the expected benefit of ICI in metastatic pRCC treatment, as PD-L1 expression is a factor of poor prognosis in this multicenter cohort.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Naffrichoux J, Poupin P, Pouillot W, et al. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort. Eur J Cancer. 2024. PMID: 38749111. doi:10.1016/j.ejca.2024.114121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。